On Mar. 18, 2021, Incyte announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients on mechanical ventilation with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).

The safety profile was generally consistent with hospitalized patients with COVID-19 and consistent with treatment with ruxolitinib.